"Idarubicin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An orally administered anthracycline antineoplastic. The compound has shown activity against BREAST NEOPLASMS; LYMPHOMA; and LEUKEMIA.
| Descriptor ID |
D015255
|
| MeSH Number(s) |
D02.455.426.559.847.562.050.200.300 D04.615.562.050.200.300 D09.408.051.059.200.300
|
| Concept/Terms |
Idarubicin- Idarubicin
- 4-Desmethoxydaunorubicin
- 4 Desmethoxydaunorubicin
- 4-Demethoxydaunorubicin
- 4 Demethoxydaunorubicin
|
Below are MeSH descriptors whose meaning is more general than "Idarubicin".
Below are MeSH descriptors whose meaning is more specific than "Idarubicin".
This graph shows the total number of publications written about "Idarubicin" by people in this website by year, and whether "Idarubicin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 1 | 0 | 1 |
| 2003 | 1 | 0 | 1 |
| 2005 | 1 | 0 | 1 |
| 2025 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Idarubicin" by people in Profiles.
-
FLAG-IDA plus venetoclax for children, adolescents, and young adults with newly diagnosed AML. Blood. 2025 Nov 20; 146(21):2608-2611.
-
Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia. JAMA. 2015 Aug 25; 314(8):811-22.
-
Prognostic significance of the Medical Research Council cytogenetic classification compared with the European LeukaemiaNet risk classification system in acute myeloid leukaemia. Br J Haematol. 2015 Aug; 170(4):590-3.
-
Identification of clinically important chromosomal aberrations in acute myeloid leukemia by array-based comparative genomic hybridization. Leuk Lymphoma. 2014 Nov; 55(11):2538-48.
-
Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia. Leukemia. 2014 Jul; 28(7):1543-5.
-
Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients =60 years with newly diagnosed acute myeloid leukemia. Am J Hematol. 2013 Nov; 88(11):961-6.
-
Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome. J Clin Oncol. 2012 Jun 20; 30(18):2204-10.
-
Elacytarabine, a novel 5'-elaidic acid derivative of cytarabine, and idarubicin combination is active in refractory acute myeloid leukemia. Leuk Res. 2012 Apr; 36(4):e71-3.
-
Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin. Cancer. 2012 May 15; 118(10):2665-73.
-
Is obesity a prognostic factor for acute myeloid leukemia outcome? Ann Hematol. 2012 Mar; 91(3):359-65.